Quick protocol for depression with intravenous ketamine.
Zenodo (CERN European Organization for Nuclear Research) July 9, 2026 DOI: 10.5281/zenodo.21284219 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Population | Patients with treatment-resistant depression |
| Intervention | Intravenous ketamine |
| Topics | Ketamine Depression Esketamine |
| Keywords | Protocol science Depression economics Intravenous drug Anesthesia Intensive care medicine Medical emergency Emergency medicine Electroconvulsive therapy studies |
| Key findings | Intravenous ketamine is supported by guidelines for treatment-resistant depression but requires careful monitoring due to variable efficacy and side effects. |
Abstract
Intravenous ketamine is used for treatment-resistant depression, with structured guidelines supporting its use, but requires careful patient monitoring due to potential side effects and variable efficacy.
Comparable studies
Other narrative reviews on ketamine for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression | 2021 | Review | |
| Ketamine: a paradigm shift for depression research and treatment | 2019 | Review | |
| Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective | 2019 | Review | |
| Ketamine: A tale of two enantiomers | 2020 | Review | |
| Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor | 2021 | Review |